Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN12140 in complement inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria
CTR20255252Phase 2Active
- Sponsor
- Linnuo Pharma
- Start
- Feb 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SLN12140 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Linnuo Pharma. Started Feb 2026; status: active.
02
Drugs
SLN12140
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20255252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255252.